In this age of healthcare, the technical challenge is no longer the greatest hurdle in the development of diagnostics. While patient access, provider confidence, and payer approval are the critical components of a successful go-to-market approach, considerations around everything from clinical workflow, system incentives, formulary structure and incorporation into software systems can all accelerate or impede the impact diagnostics will have on patients and in the market. Our approach considers the entire chain from beginning to end, starting with the MATE™.
WOrk with us
Checkmate!
We termed the level of evidence required for coverage the MATE™—the Minimally Acceptable Threshold of Evidence. MATE™ helps us answer these important questions so we can efficiently capitalize diagnostic companies to deliver high value tools for payers because we solve the biggest problem in diagnostics upfront.
Prior to Alva10, diagnostic companies were not able to work with payers pre-commercially to determine the clinical utility their products should have, or the level of evidence that would be required for a payer to cover the technology.
We work with payers to identify both the clinical and economic utility to frame the value proposition for the diagnostic, AND determine the level of evidence required for coverage. We then contractually commit to those standards.
When payer partners and a diagnostic company can agree on a MATE™ upfront, the win-win-win is clear:
1) The diagnostic company is able to fund
and and generate the required data.
2) The payer agrees with the clinical utility,
economic impact, data development plan
and reimbursement amount, and does not
waste resources reviewing insufficient
evidence.
3) The investors understand the path to
obtaining their ROI.
How much evidence? What type of evidence? What is the reimbursement?
We termed the level of evidence required for coverage the MATE™—the Minimally Acceptable Threshold of Evidence. MATE™ helps us answer these important questions so we can efficiently capitalize diagnostic companies to deliver high value tools for payers because we solve the biggest problem in diagnostics upfront.
Prior to Alva10, diagnostic companies were not able to work with payers pre-commercially to determine the clinical utility their products should have, or the level of evidence that would be required for a payer to cover the technology.
We work with payers to identify both the clinical and economic utility to frame the value proposition for the diagnostic, AND determine the level of evidence required for coverage. We then contractually commit to those standards.
When payer partners and a diagnostic company can agree on a MATE™ upfront, the win-win-win is clear:
1) The diagnostic company is able to fund and generate the required data.
2) The payer agrees with the clinical utility, economic impact, data development plan and reimbursement amount, and
does not waste resources reviewing insufficient evidence.
3) The investors understand the path to obtaining their ROI.
How much evidence? What type of evidence? What is the reimbursement?
SOLVING THE ‘HOLY GRAIL’ PROBLEM IN DIAGNOSTICS
M.A.T.E™
Alva10 works with Diagnostic developers and payers in tandem to create value across the precision medicine ecosystem
Confirms presence & size of market, ROI potential
Adds commercial and reimbursement/payment strategy to forefront of research and development planning
Reduces time to market, most efficient use of capital
Yields high value, reimbursed, tools for healthcare
*Evaluate for commercial viability
*Determine clinical utility
*Build budget impact model
*Calculate value-based reimbursement/payment
*Identify disease/cost areas of interest
based on prevalence
*Derive clinical needs in population
*Determine economics of novel technology
Diagnostic developers
Payers
The Alva10 Difference
You are a
PAYER
A traditionally recognized Healthcare Payer
You are an
Employer
Looking to improve company healthcare benefits/spending
You are a
Diagnostic
Developer
Lab
or
Innovating technology
You are an
Investor
Exploring ways to invest in innovative technologies
Alva10 understands that each of our partnering groups has a different understanding of utility in this area of healthcare. By choosing your affiliation you will gain the best and most focused insight on how we support and partner with you.
